TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07033598: Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia

Sponsor: Theradex · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 66 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$554,400

Rescue Site Savings

+$369,600

Unlock Full NCT07033598 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07033598 Rescue Dossier →